Trial Profile

A Proof-of-Concept Phase II, Open-Label Study of NM8074 in Patients with Dermatomyositis (DM)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxoprubart (Primary)
Indications Dermatomyositis
Focus Proof of concept; Therapeutic Use
Sponsors NovelMed Therapeutics

Most Recent Events

20 Mar 2025 Status changed from planning to not yet recruiting.
26 Feb 2025 New trial record
24 Feb 2025 According to a NovelMed Therapeutics media release, this announcement from company regarding FDA approval follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where Ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com